Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NovoCure Limited
  6. News
  7. Summary
    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
79.89 USD   +4.05%
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : NovoCure Limited, Q2 2021 Earnings Call, Jul 29, 2021

07/29/2021 | 08:00am EDT
share with twitter
share with LinkedIn
share with facebook
Good day, ladies and gentlemen. Thank you for standing by. Welcome to the NovoCure Second Quarter 2021 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference may...


© S&P Capital IQ 2021
All news about NOVOCURE LIMITED
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -102x
Yield 2022 -
Capitalization 8 368 M 8 368 M -
EV / Sales 2022 15,5x
EV / Sales 2023 14,6x
Nbr of Employees 1 167
Free-Float 86,8%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 79,89 $
Average target price 94,25 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED6.41%8 368
SHOCKWAVE MEDICAL, INC.55.56%9 967
MASIMO CORPORATION-46.11%8 757
PENUMBRA, INC.-39.77%6 557
GETINGE AB-45.18%6 026
IRAY TECHNOLOGY COMPANY LIMITED2.13%5 476